APA (7th ed.) Citation

Di Bacco, A., Bahlis, N. J., Munshi, N. C., Avet‐Loiseau, H., Masszi, T., Viterbo, L., . . . Moreau, P. (2020). c‐MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide‐dexamethasone in myeloma. European journal of haematology, 105(1), 35-46. https://doi.org/10.1111/ejh.13405

Chicago Style (17th ed.) Citation

Di Bacco, Alessandra, et al. "C‐MYC Expression and Maturity Phenotypes Are Associated with Outcome Benefit from Addition of Ixazomib to Lenalidomide‐dexamethasone in Myeloma." European Journal of Haematology 105, no. 1 (2020): 35-46. https://doi.org/10.1111/ejh.13405.

MLA (9th ed.) Citation

Di Bacco, Alessandra, et al. "C‐MYC Expression and Maturity Phenotypes Are Associated with Outcome Benefit from Addition of Ixazomib to Lenalidomide‐dexamethasone in Myeloma." European Journal of Haematology, vol. 105, no. 1, 2020, pp. 35-46, https://doi.org/10.1111/ejh.13405.